Company profile
ProMIS Neurosciences Inc. - logo

ProMIS Neurosciences Inc. -

Pipeline5 assets

  • PMN310PMN310 / Amyloid-Beta / Monoclonal Antibody / Neurology
    Alzheimer's Disease
  • PMN267PMN267 / TDP-43 / Monoclonal Antibody / Neurology
    Amyotrophic Lateral Sclerosis (ALS)Frontotemporal Dementia (FTD)Limbic-predominant age-related TDP-43 encephalopathy (LATE)
  • PMN442PMN442 / Alpha-Synuclein / Monoclonal Antibody / Neurology
    Parkinson's Disease (PD)Multiple System Atrophy (MSA)Dementia with Lewy Bodies (DLB)
  • PMN311PMN311 / Amyloid-Beta / Vaccine / Neurology
    Alzheimer's Disease
  • PMN440PMN440 / Alpha-Synuclein / Vaccine / Neurology
    Parkinson's Disease

Latest news9 items

All news

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers Represents one of the first quantitative measures of treatment-related effects on oligomer levels in a clinical trial Company on track to present six-month blinded interim data from its Phase 1b trial in the...

Presentation / Abstract • Phase 1AAIC poster presentation Tue, Jul 14, 2026, 7:30 AM

ProMIS Neurosciences to Participate in Upcoming Conferences in June

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one...

ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)

Cambridge, Massachusetts, March 18, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that it will present two scientific posters at the Alzheimer’s & Parkinson’s Diseases Conference...

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the company will be participating in a fireside chat and investor one-on-one meetings at the...

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

Extends cash runway into 2028 Proceeds expected to enable completion of ProMIS’ landmark Phase 1b AD study and support execution of key clinical milestones Blinded 6-month top-line data expected mid-2026; 12-month top-line data expected toward end of 2026 CAMBRIDGE, Massachusetts , Jan. 30, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq:...